| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | President and CEO
1 company
Christopher Richard Anzalone is Chief Executive Officer at ARWR. Christopher Richard Anzalone's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $225.8M at current prices.
Historically, Christopher Richard Anzalone's trades have earned a middling insider score of 60/100 across 27 rated trades. Over a 12-month horizon, 55.0% of those trades were profitable, with an average 12-month return of -24.1%.
The ARWR filings lean toward selling, a net 3,054,419 shares.
Christopher Richard Anzalone has 57 Form 4 filings on record from March 2015 to January 2026, all as Chief Executive Officer at Arrowhead Pharmaceuticals (ARWR), 2015–2026.
The 153 reported transactions were 106 open-market sales, 26 option exercises, 14 stock awards and 2 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 37 sales worth about $109.0M.
The largest open-market sale was 184,298 shares of ARWR at an average $67.00 on December 16, 2025, about $12.3M.
11 of the 17 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 6 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sell10b5-1 | 13,187 | $66.10 | $871,702.77 | -0.3% | -10.0% | - | |
| Dec 29, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 51,726 | $69.13 | $3,575,574.78 | -1.3% | -17.2% | - | |
| Dec 22, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sell10b5-1 | 26,031 | $68.04 | $1,771,022.38 | -0.7% | -17.9% | - | |
| Dec 17, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sell | 85,000 | $64.04 | $5,443,462.11 | -2.2% | -11.2% | - | |
| Dec 16, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sell | 184,298 | $67.00 | $12,348,801.97 | -4.5% | -11.3% | - | |
| Apr 11, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sell | 141,122 | $10.87 | $1,533,336.57 | -3.5% | +60.0% | +452.5% | |
| Mar 13, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sell | 51,425 | $15.07 | $774,974.75 | -1.3% | +11.1% | +265.3% | |
| Mar 4, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE10b5-1 | 300,000 | $17.58 | $5,274,333.67 | -7.4% | -4.1% | +280.5% | |
| Jan 2, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sell10b5-1 | 11,520 | $19.05 | $219,456.00 | -0.3% | -35.4% | +245.0% | |
| Dec 23, 2024 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Executive Officer | Sell10b5-1 | 12,563 | $19.59 | $246,109.17 | -0.3% | -21.5% | +253.6% |